TD Cowen Sticks to Its Buy Rating for Tenet Healthcare (THC)

In a report released today, Ryan Langston from TD Cowen maintained a Buy rating on Tenet Healthcare, with a price target of $230.00.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Langston is an analyst with an average return of -8.7% and a 37.50% success rate. Langston covers the Healthcare sector, focusing on stocks such as Elevance Health, Acadia Healthcare, and Centene.

Currently, the analyst consensus on Tenet Healthcare is a Strong Buy with an average price target of $241.80.

Based on Tenet Healthcare’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $5.29 billion and a net profit of $342 million. In comparison, last year the company earned a revenue of $5.12 billion and had a net profit of $472 million

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of THC in relation to earlier this year. Last month, Nadja West, a Director at THC sold 2,178.00 shares for a total of $430,089.66.